Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 05-13642 |
Not provided
Not provided
Not provided
Not provided
Lack of recruitment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Statins are medications that lower blood cholesterol by inhibiting cholesterol production in the liver. Overall, statins are well tolerated. Approximately 10% to 15% of patients report muscle aches/pain while taking statins. In a very small percentage of patients (<0.01%; less than one in 10,000 people), muscle aches/pains may be accompanied by more serious muscle damage. In these patients, statins must be discontinued. In some reports, patients taking statins have reduced blood levels of coenzyme Q10. Coenzyme Q10 is an essential protein which is present in all human cells needed for normal cell function. Coenzyme Q10 has been tested in patients with heart failure where it has been shown to be safe and effective. Many patients with heart conditions take coenzyme Q10, but the risks and benefits of supplementation with this product is unknown. Coenzyme Q10 is considered a dietary supplement and is not approved by the Food and Drug Administration (FDA) for any medical condition. Coenzyme Q10 has very few, if any, side effects. Upset stomach (gastritis), headache, body ache, and low blood pressure have been reported. The objectives of this project are to test the efficacy and safety of coenzyme Q10 in treating muscle aches/pain in patients already taking statins who develop these symptoms.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator |
| |
| 2 | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| coenzyme Q10 | Dietary Supplement | 60mg capsule twice daily for 12 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| evaluate the efficacy coenzyme Q10 in the treatment of myalgia in patients receiving statin therapy | every 3-5 days during the first week 2 weeks, then at 4 weeks and 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| evaluate the safety of coenzyme Q10 in the treatment of myalgia in patients receiving statin therapy | every 3-5 days during the first week 2 weeks, then at 4 week and 12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robyn Kondrack, PharmD | Creighton University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Cardiac Center of Creighton University Medical Center | Omaha | Nebraska | 68131 | United States |
Not provided
| ID | Term |
|---|---|
| D063806 | Myalgia |
| ID | Term |
|---|---|
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C024989 | coenzyme Q10 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| matching placebo |
| Dietary Supplement |
matching placebo capsule twice daily for 12 weeks |
|
| D059352 | Musculoskeletal Pain |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |